Search

everythinglearnresearchcommunity

for

Search:↓

Hair cloning is being developed by companies like Kangstem Biotech and Stemson, with potential availability in a few years. Initial costs are expected to be high, but prices may decrease over time.

The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.

Microneedling with exosomes is being considered for hair regrowth, but concerns exist about their effectiveness and safety, especially since exosomes degrade quickly and lack FDA approval. The user is seeking alternatives for non-responders to minoxidil and dutasteride, as exosomes may not provide additional benefits.

SCUBE3 clinical trials for hair loss treatment to start this year. Treatment may involve regular, painless scalp injections to maintain hair growth.

Kintor Pharma announced successful Phase II trial results for KX-826 in treating hair loss, showing it's comparable to finasteride and can be used with it. Some participants saw a 10 hair/cm^2 increase, which is considered a good outcome at the low dose used.

The conversation discusses Scube3, a seemingly new and obscure treatment for hair loss, with limited information available and a link to a patient intake form.

Essential oils like rosemary, thyme, lavender, and cedar wood in a carrier oil may effectively treat alopecia areata and potentially male pattern baldness by stimulating the scalp similarly to minoxidil. The user plans to try this routine and share results.

A user shared their positive experience with a 2987 graft hair transplant focused on the hairline, supplemented by finasteride and minoxidil for the mid scalp and crown. They expressed satisfaction with the results and the supportive care received during and after the procedure.

A user experienced hair thinning due to traction alopecia from using Murray's Beeswax and is considering treatments like minoxidil and finasteride to reverse the damage. Another user suggests consulting a hair specialist, as the hair may not regrow if scar tissue has formed.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

The user is using RU58841 for hair regrowth on the temples and is considering adding minoxidil. They are questioning the potential for vellus hairs to develop into fuller hair and the possibility of reactivating dormant follicles.

A 28-year-old male experiencing diffuse thinning and miniaturization around the ears and back has tried finasteride, dutasteride, and both topical and oral minoxidil without success. He is seeking advice on identifying the type of hair loss and next steps since current treatments are ineffective.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

Verteporfin is being discussed for its potential to regrow hair and heal scars, possibly aiding hair transplants or replacing them. Some users are skeptical about its effectiveness, while others suggest combining it with microneedling for better results.

The conversation is about the anticipation and uncertainty regarding the release of GT20029 Phase 2 results for hair loss treatment. Users express hope for its effectiveness and minimal side effects compared to other treatments like Pyri and HMI115.

Exosomes are discussed as a new hair loss treatment, but skepticism is expressed about their effectiveness. Other treatments mentioned include Minoxidil, finasteride, and RU58841.

The user shared progress on hair loss treatment using Nanoxidil, which initially caused scalp irritation. They are pleased with their progress since starting the treatment in March.

Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.

After experiencing hair loss due to alopecia areata following COVID-19 vaccination and infection, the individual saw improvement with steroid treatments and Olumiant. They paused Olumiant during a second COVID-19 infection and expressed concern about potential hair loss flare-ups.

The conversation is about a person rapidly losing hair and seeking information on the availability of a new treatment called scube3, as they have experienced side effects from current treatments like Minoxidil and finasteride. They are hoping scube3 will be approved soon as they believe it's their only remaining option.

The conversation discusses the potential of using topical estrogen treatments for hair loss without systemic absorption, highlighting challenges and possible solutions like using estriol. It also mentions other treatments like topical finasteride, microneedling, and scalp massage, while noting the limitations and side effects of current options.

ShaneMorcs shared updated hair comparison photos and believes he's made progress. People commented on his improvement, asked about potential side effects, and inquired about the treatments he's using.

The user is experiencing a strange hair loss pattern despite using dutasteride for 3 years and minoxidil with tretinoin for 1.5 years. They recently added microneedling and are considering a scalp biopsy to understand the cause.

A user shared their positive experience with a hair transplant performed by Dr. Timothy Carman, using 1100 grafts via FUT surgery, and reported satisfaction with the results and minimal scarring. The user continues to use minoxidil and finasteride for hair maintenance.

HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.

Hair loss recovery using estrogen and anti-androgen treatment for 18 months showed significant improvement. However, results vary and alternative treatments like RU58841 and Dutasteride may work without systemic feminization.

A user is considering switching from oral to topical finasteride to reduce systemic DHT impact and is exploring ethossomal finasteride for better skin penetration and potential hair regrowth. They found ethossomal finasteride in Brazil and are seeking opinions on its effectiveness compared to other topical delivery methods.

Selenium sulfide shampoo helped with a sore scalp but may cause hair root damage. Users experienced hair loss with selenium sulfide and ketoconazole, suggesting reducing use if hair loss occurs.

A user solved their 15-year scalp inflammation and related hair loss using Selenium Sulfide shampoo (Selsun Blue), noticing improvement after the first use and resolution after three uses. Others found relief with Ketoconazole shampoo, which also helps with hair loss.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.